Apixaban

Apixaban Reactions 1704, p45 - 2 Jun 2018 Frailty: case report A 92-year-old man developed frailty during treatment with apixaban for non-occlusive deep vein thrombosis of right femoral, popliteal and proximal posterior tibial veins. The man, who had chronic lymphocytic leukaemia, immune thrombocytopenic purpura, hypertension, hyperlipidaemia, was started on apixaban 2.5mg twice daily [route not stated] for non-occlusive deep vein thrombosis of right femoral, popliteal and proximal posterior tibial veins. Initially, the medication was tolerated. However, two months later, he started having generalised weakness, decreased appetite and increased tendency to fall. He had few falls at home, weight loss of around ten pounds, fatigue and reduced activity level. Based on these symptoms fraility was confirmed. His haemoglobin, metabolic panel and thyroid stimulating hormone were normal. After ruling out infectious and metabolic causes, his frailty was attributed to apixaban. After completing three months treatment of apixaban, it was stopped after haematology consultation. The man began feeling well with improved appetite, fatigue and activity level. At follow-up, he was back to his baseline performance status. Author comment: "We report a case of frailty in elderly patient due to apixaban use." Priyambada P, et al. Frailty associated with apixaban: A case report and review of literature. Journal of the American Geriatrics Society 66 (Suppl. 2): S184, Apr 2018. Available from: URL: http://doi.org/10.1111/jgs.15376 [abstract] - USA 803323549 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Apixaban

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/apixaban-B1yVfSDX00
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46688-4
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p45 - 2 Jun 2018 Frailty: case report A 92-year-old man developed frailty during treatment with apixaban for non-occlusive deep vein thrombosis of right femoral, popliteal and proximal posterior tibial veins. The man, who had chronic lymphocytic leukaemia, immune thrombocytopenic purpura, hypertension, hyperlipidaemia, was started on apixaban 2.5mg twice daily [route not stated] for non-occlusive deep vein thrombosis of right femoral, popliteal and proximal posterior tibial veins. Initially, the medication was tolerated. However, two months later, he started having generalised weakness, decreased appetite and increased tendency to fall. He had few falls at home, weight loss of around ten pounds, fatigue and reduced activity level. Based on these symptoms fraility was confirmed. His haemoglobin, metabolic panel and thyroid stimulating hormone were normal. After ruling out infectious and metabolic causes, his frailty was attributed to apixaban. After completing three months treatment of apixaban, it was stopped after haematology consultation. The man began feeling well with improved appetite, fatigue and activity level. At follow-up, he was back to his baseline performance status. Author comment: "We report a case of frailty in elderly patient due to apixaban use." Priyambada P, et al. Frailty associated with apixaban: A case report and review of literature. Journal of the American Geriatrics Society 66 (Suppl. 2): S184, Apr 2018. Available from: URL: http://doi.org/10.1111/jgs.15376 [abstract] - USA 803323549 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off